Insmed (INSM) PT Raised to $108 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts INSM Hot Sheet
Price: $110.00 +5.32%
Rating Summary:
31 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 28 | New: 13
Rating Summary:
31 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 28 | New: 13
Join SI Premium – FREE
RBC Capital analyst Leonid Timashev raised the price target on Insmed (NASDAQ: INSM) to $108.00 (from $106.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Insmed (INSM) PT Lowered to $201 at Guggenheim
- Pfizer (PFE) PT Raised to $40 at Argus
- Insmed to Present at November and December 2026 Investor Conferences
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
